← Back to Clinical Trials
Recruiting NCT07567885

NCT07567885 Brief Cognitive Behaviour Therapy to Prevent Suicide Reattempts: A Feasibility Study in Swedish Psychiatric Inpatient Care

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07567885
Status Recruiting
Phase
Sponsor Karolinska Institutet
Condition Suicide Attempt
Study Type INTERVENTIONAL
Enrollment 32 participants
Start Date 2026-05-11
Primary Completion 2026-12-14

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Brief Cognitive Behaviour Therapy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 32 participants in total. It began in 2026-05-11 with a primary completion date of 2026-12-14.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this study is to determine whether Brief Cognitive Behaviour Therapy (BCBT), a four-session psychological treatment aimed at reducing suicide attempts, is acceptable and feasible to deliver during psychiatric inpatient care for adults who have been hospitalised following a suicide attempt or who are at high risk of suicide. The main questions it aims to answer are: 1. Is BCBT acceptable among suicidal psychiatric inpatients, and in what ways can the treatment and its delivery be improved to enhance patient engagement and adherence? 2. Is BCBT feasible from the perspectives of treating clinicians, clinic managers, and other relevant personnel, and what are the key facilitators and barriers to its implementation within routine inpatient psychiatric care in Sweden? Participants will: * Receive four structured BCBT therapy sessions delivered during hospitalisation, in addition to usual care * Be contacted for follow-up assessments at 1 and 3 months after completing treatment * Take part in an interview about the participants' experience with the treatment 1 month after completing it Clinical staff, treating psychologists, and managers will also be interviewed to explore the participants' experiences, as well as barriers and facilitators to implementation. Overall, the findings from this study will inform the design of a future randomised trial to test the effectiveness of BCBT in reducing suicide attempts after discharge from inpatient psychiatric care.

Eligibility Criteria

Inclusion Criteria: * admitted following a suicide attempt within one week of admission or presenting with suicidal ideation with a plan and a prior suicide attempt within the last two years * 18 years or older Exclusion Criteria: * current mania, current acute psychosis, or cognitive impairment * expected inpatient stay shorter than four working days * ongoing or planned electroconvulsive therapy * psychiatric or somatic conditions leading to inability to provide informed consent

Contact & Investigator

Central Contact

Christian Rück, Professor

✉ christian.ruck@ki.se

📞 +46704843392

Frequently Asked Questions

Who can join the NCT07567885 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Suicide Attempt. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07567885 currently recruiting?

Yes, NCT07567885 is actively recruiting participants. Contact the research team at christian.ruck@ki.se for enrollment information.

Where is the NCT07567885 trial being conducted?

This trial is being conducted at Stockholm, Sweden.

Who is sponsoring the NCT07567885 clinical trial?

NCT07567885 is sponsored by Karolinska Institutet. The trial plans to enroll 32 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology